
Accuray (ARAY) Stock Forecast & Price Target
Accuray (ARAY) Analyst Ratings
Bulls say
Accuray is a leading company in the radiation oncology industry, with its advanced technology and highly precise treatment solutions setting the standard for patient care. However, recent pressures from geopolitical uncertainty and lumpy reporting quarters have hindered the company's operating performance, and the lack of progress on commercial execution and profitability metrics may continue to impact the company's growth. While there is potential for an improved geopolitical backdrop and increased orders in the future, there are also significant risks to consider such as potential dilution, product delays, and challenges in the supply chain and reimbursement.
Bears say
Accuray is facing challenges in commercial execution and profitability, with a lack of progress and a lengthy timeline for improvement. They have also been impacted by geopolitical tensions, potential tariffs and supply chain issues. Despite trading at a discount compared to peers, the analyst has a neutral rating due to these concerns.
This aggregate rating is based on analysts' research of Accuray and is not a guaranteed prediction by Public.com or investment advice.
Accuray (ARAY) Analyst Forecast & Price Prediction
Start investing in Accuray (ARAY)
Order type
Buy in
Order amount
Est. shares
0 shares